Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

9
Why should investors stay away from firms facing insolvency proceeding?

2018-06-26 moneycontrol
Irrespective of market conditions and instruments it is always better to stay away from speculation and manipulation. Jessi Livermore the biggest trader of the last century once said, “The game of speculation is the most uniformly fascinating game in the world. But it is not a game for the stupid, the mentally lazy, the person of inferior emotional balance, or the get rich quick adventurer. They will die poor.
ESL SUZLON BHUSANSTL 533264 532778 532667 500470 TTST TATASTEEL TATLY LITL SUEL 500055

24
Market Update: RIL top Nifty gainer, hits new record high; ICICI, Indigo up 1-2%, Infratel down 3%

2018-06-21 moneycontrol
The broader indices including the Nifty and the Sensex are trading on a positive note this Thursday morning with the Nifty up 7 points at 10,779 and the Sensex is trading higher by 31 points at 35,578.
SUZLON 500325 TCHQY 532514 532755 SHREECEM IGL 534816 SUEL RLNIY 524804 TATAPOWER APOLLOTYRE AYRQY 532667 TECHM BATAINDIA TATASTEEL TATLY 500180 500387 BHRYY AUROPHARMA GODREJIND RELIANCE 500470 532461 RIGD INFRATEL HDFCBANK INDIGO 517354 HVLQY 500877 IBN 539207 539448 ICICIBANK TTST PNJZY HDB 532174 ARBQY HAVELLS TPCL PNB 500400 500043 500164 MANPASAND

28
Closing Bell: Sensex up 416 pts, Nifty ends May series above 10,700; HDFC Bank leads

2018-05-31 moneycontrol
Fundraising: Multiplex operator PVR is evaluating acquisition opportunities of cinema exhibition chains and plans to raise funds to carry out the transaction through issuance of non convertible debentures (NCDs).
IOC SUZLON ARCHIDPLY CAPF TCHQY 532755 532710 532400 KPIT TORNTPOWER 500570 SUEL CLNDY EVSJF 530965 532667 TECHM 532994 500182 500180 520051 KOTAKBANK 534809 PCJEWELLER COALINDIA HINDCOPPER 532938 532779 533278 532541 532187 HDFCBANK HEROMOTOCO SADBHAV TATAMOTORS NIITTECH ESI INDUSINDBK KMBKY IBN 513599 539207 ICICIBANK HDB 532174 JAMNAAUTO HRTQY 500247 MANPASAND TTM

0
Suzlon Energy Limited - Outcome of Board Meeting

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUZLON 532667 SUEL

0
Suzlon Energy Limited - Financial Result Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SUZLON 532667 SUEL

55
Goldman Sachs’ ReNew Power stake sale to be biggest IPO exit by a PE firm in India

2018-05-27 livemint
Mumbai: Goldman Sachs Group Inc.’s planned $600 million stake sale in ReNew Power Ventures Pvt. Ltd will mark the biggest exit for a private equity fund through an initial share sale in India.
JBK SUZLON GS.PRICL GSC TFG GS.PRB GS.PRA 532667 GSJ GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN SUEL GS.PRK

1
Suzlon in talks to sell 300 MW of wind power assets

2018-05-23 livemint
Mumbai: Suzlon Energy Ltd, which is exploring the sale of 300 megawatts (MW) of wind power assets, has hired an investment bank to manage the process, said two people aware of the development.
SUZLON TATAPOWER TPCL U96 500400 SCRPF 532667 SUEL SCRPY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...